Side Effects

Gastroparesis and GLP-1: Separating Risk from Reality

GLP-1 Companion · 7 min read

Every time a GLP-1 receptor agonist is described as helping patients feel full longer, that mechanism involves the stomach. These medications slow gastric emptying — the rate at which food moves from the stomach into the small intestine. Under normal circumstances and in the right patients, this is a therapeutically desirable effect that reduces hunger and caloric intake. But the same mechanism raises legitimate questions about gastroparesis — a condition in which gastric emptying becomes pathologically delayed.

What Is Gastroparesis?

Gastroparesis is a condition characterized by significantly delayed gastric emptying in the absence of a mechanical obstruction. The stomach's muscles and the nerves that coordinate them are not functioning properly, leaving food sitting in the stomach far longer than it should. This causes chronic nausea, vomiting, bloating, early satiety, and in severe cases, malnutrition and recurrent hospitalizations.

The most common cause of gastroparesis is diabetes — specifically, long-standing diabetes that has caused autonomic neuropathy affecting the vagus nerve, which orchestrates gastric motility. Other causes include previous gastric surgery, certain viral infections, and connective tissue disorders. For a significant proportion of cases, the cause is never identified (idiopathic gastroparesis).

The FDA Safety Communication

In 2023, the FDA issued a safety communication acknowledging that it had received multiple reports of severe gastroparesis — requiring hospitalization in some cases — in patients using GLP-1 receptor agonists. This followed case reports and pharmacovigilance signals identifying patients who developed severe gastric motility impairment that was temporally associated with starting these medications.

The communication prompted updated labeling discussions and heightened clinical awareness, though the FDA stopped short of requiring new boxed warnings, reflecting the challenge of establishing causality in conditions like gastroparesis that have many predisposing factors.

Who Is at Highest Risk?

The risk of clinically significant gastroparesis from GLP-1 medications is not evenly distributed across the patient population.

• Patients with pre-existing diabetic gastroparesis: These individuals already have impaired gastric motility. Adding a medication that further slows gastric emptying can tip the balance into severely symptomatic disease.
• Patients with diabetic autonomic neuropathy: Even without a prior gastroparesis diagnosis, those with evidence of autonomic nerve damage are at higher risk.
• Long-standing type 2 diabetes: Duration of diabetes correlates with neuropathy risk.
• Prior symptoms of delayed gastric emptying: Patients who have noticed that meals sit heavily for hours, or who have recurrent nausea after eating, may have subclinical gastroparesis.
• Use of other medications that slow gastric motility: Opioids, anticholinergics, and certain antidepressants also slow gastric emptying and compound the effect.

Normal GLP-1 Effects vs. Dangerous Gastroparesis

Distinguishing between the expected side effects of GLP-1 therapy and the warning signs of true gastroparesis is clinically important:

Expected GLP-1 Effects (Common and Manageable)

• Nausea, particularly in the first weeks of treatment and during dose escalation
• Feeling full after small amounts of food
• Reduced appetite throughout the day
• Mild bloating or slow digestion after meals
• These effects typically diminish as the body adjusts and should not worsen at stable dose

Warning Signs of Gastroparesis (Require Medical Evaluation)

• Vomiting of food that was eaten more than 3 hours earlier — food that clearly has not been digested or moved forward
• Persistent, severe nausea that does not improve between doses or improve with dose stabilization
• Severe abdominal pain or persistent cramping, particularly in the upper abdomen
• Inability to tolerate any food or liquids without vomiting
• Significant unintentional weight loss beyond expected drug effect
• Symptoms that worsen rather than improve over time at stable dose

A Critical Safety Note: GLP-1 and Surgery

This is one of the most important practical implications of GLP-1's gastric emptying effect, and it is frequently overlooked by both patients and surgical teams.

Standard pre-operative fasting guidelines (nothing by mouth after midnight, or "NPO after midnight") are designed to ensure that the stomach is empty before anesthesia, preventing aspiration of stomach contents into the lungs — a potentially fatal complication. These guidelines were developed for patients with normal gastric emptying.

GLP-1 medications slow gastric emptying so substantially that the stomach may not be empty even after a standard overnight fast. Patients who followed NPO instructions have been found to have food residue in their stomachs at the time of intubation — creating aspiration risk.

Multiple professional anesthesia societies now recommend that patients on GLP-1 medications follow extended fasting periods (often 24 hours for solid food) before elective procedures, and that gastric ultrasound assessment be considered before induction. Some guidelines recommend holding the medication for 1-4 weeks before elective surgery, though this must be balanced against glycemic control concerns in diabetic patients.

What to Tell Your Healthcare Team

If you have any of the following, discuss gastroparesis risk with your prescriber before starting or continuing GLP-1 therapy:

• History of gastroparesis or abnormal gastric emptying study
• Long-standing diabetes with autonomic symptoms (dizziness on standing, abnormal sweating, early satiety)
• Regular use of opioids or other motility-impairing medications
• Prior gastric or bariatric surgery
• Current symptoms of possible delayed gastric emptying

The Balanced Reality

Gastroparesis is a serious condition. The FDA communication and clinical case reports are real signals that deserve attention. At the same time, tens of millions of patients use GLP-1 medications without developing pathological gastroparesis. The risk is real but concentrated in identifiable high-risk groups, primarily those with pre-existing diabetic gastric nerve damage. For the broader weight-loss population, the gastric slowing is a therapeutic tool, not a danger — provided that the surgical fasting warning is universally observed and that patients know which symptoms distinguish normal drug effects from a problem requiring evaluation.

Sources

• Ozempic (semaglutide) Prescribing Information. Novo Nordisk.
• Drucker DJ (2018). Mechanisms of Action and Therapeutic Application of GLP-1. Cell Metabolism.